Biotechnology company Abilita Bio Inc disclosed on Wednesday the launch of a research collaboration agreement with Amgen, a biotechnology company, for drugs targeting complex membrane proteins.
This agreement allows Abilita Bio to leverage its proprietary Enabled Membrane Protein (EMP) technology platform to support Amgen's R&D efforts on challenging integral membrane protein targets.
According to Abilita, its EMP technology couples high-throughput mutagenesis to a robust microbial selection system in order to evolve membrane protein target variants that demonstrate transformative improvements in their biophysical properties, while preserving relevant folding and function. The EMP technology platform was developed to address the difficulties in working with the most challenging and medically important drug target classes including G Protein-Coupled Receptors, Ion Channels and Transporters, thereby providing unprecedented access to modern methods for the discovery of therapeutic antibodies and small molecules.
The financial details of the agreement were not disclosed by the companies.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval